专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006017673A3 TAJ IN NEURONAL FUNCTION 审中-公开
标题翻译：神经功能的TAJ
公开(公告)号：WO2006017673A3
公开(公告)日：2007-04-12
申请号：PCT/US2005027773
申请日：2005-08-03
申请人： BIOGEN IDEC INC , MI SHA , BROWNING JEFFREY L
发明人： MI SHA , BROWNING JEFFREY L
IPC分类号： A01N37/18
CPC分类号： A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0356 , A61K38/191 , A61K48/00 , A61K2039/505 , C07K14/70578 , C07K16/2878 , C07K2319/30 , C12N5/0619 , C12N15/8509 , C12N2501/25 , C12N2517/02 , G01N2333/70575
摘要： The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist.
摘要翻译：本发明提供了通过施用TAJ拮抗剂治疗疾病，病症，损伤或涉及调节神经突生长和/或存活（包括CNS疾病，中风或脊髓损伤）的病症的方法。

2. 发明申请

WO2005092927A1 RECEPTOR COUPLING AGENTS AND THERAPEUTIC USES THEREOF 审中-公开
标题翻译：受体偶联剂及其治疗用途
公开(公告)号：WO2005092927A1
公开(公告)日：2005-10-06
申请号：PCT/US2005/009967
申请日：2005-03-23
申请人： BIOGEN IDEC MA INC. , BROWNING, Jeffrey, L. , BAILLY, Veronique , GARBER, Ellen
发明人： BROWNING, Jeffrey, L. , BAILLY, Veronique , GARBER, Ellen
IPC分类号： C07K16/28
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/31 , C07K2317/73 , C07K2317/75 , C07K2319/00 , G01N33/6863 , G01N2333/70575
摘要： Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed.
摘要翻译：公开了受体偶联剂，包括包含抗TNF受体结合部分的多价构建体，用于治疗癌症并抑制受试者的肿瘤体积。

3. 发明申请

WO0162790A3 NUCLEAR FACTOR POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME 审中-公开
标题翻译：核因子多核苷酸和核酸编码
公开(公告)号：WO0162790A3
公开(公告)日：2002-02-07
申请号：PCT/US0105864
申请日：2001-02-23
申请人： CURAGEN CORP , BIOGEN INC , PEYMAN JOHN A , CARULLI JOHN , BROWNING JEFFREY L
发明人： PEYMAN JOHN A , CARULLI JOHN , BROWNING JEFFREY L
IPC分类号： A61K38/00 , A61K48/00 , C07K14/47 , C12N15/12 , A61K38/17 , A61K39/395 , C07K16/18 , C12N5/10 , C12Q1/68 , G01N33/53
CPC分类号： C07K14/4702 , A01K2217/05 , A61K38/00 , A61K48/00
摘要： The present invention provides PNF1, a novel isolated polypeptide, as well as a polynucleotide encoding PNF1 and antibodies that immunospecifically bind to PNF1 or any derivative, variant, mutant, or fragment of the PNF1 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the PNF1 polypeptide, polynucleotide and antibody are used in detection and treatment of a broad range of pathological states, as well as to other uses.
摘要翻译：本发明提供PNF1，一种新型分离的多肽，以及编码PNF1的多核苷酸和免疫特异性结合PNF1或PNF1多肽，多核苷酸或抗体的任何衍生物，变体，突变体或片段的抗体。本发明还提供了其中PNF1多肽，多核苷酸和抗体用于检测和治疗广泛范围的病理状态以及其它用途的方法。

4. 发明申请

WO1996022788A1 LYMPHOTOXIN-'alpha'/'beta' COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS 审中-公开
标题翻译： LYMPHOTOXIN-α/β复合物和抗-LYMPHOTOXIN-BETA受体抗体作为抗肿瘤剂
公开(公告)号：WO1996022788A1
公开(公告)日：1996-08-01
申请号：PCT/US1996001386
申请日：1996-01-26
申请人： BIOGEN, INC. , BROWNING, Jeffrey, L. , MEIER, Werner , BENJAMIN, Christopher, D.
发明人： BIOGEN, INC.
IPC分类号： A61K38/19
CPC分类号： C07K16/2866 , A61K38/191 , A61K39/395 , A61K39/39541 , A61K2039/505 , C07K14/525 , C07K14/715 , C07K2317/73 , C07K2317/74 , C07K2319/00 , C07K2319/30 , A61K2300/00
摘要： This invention relates to compositions and methods useful for activating LT- beta receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin- alpha and multiple subunits of lymphotoxin- beta , which induce cytotoxic effects on tumor cells in the presence of lymphotoxin- beta receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin- beta receptor which act as lymphotoxin- beta receptor activating agents alone or in combination with other lymphotoxin- beta receptor activating agents either in the presence or absence of lymphotoxin- alpha / beta complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin- beta receptor antibodies either alone or in the presence of other lymphotoxin- beta receptor activating agents to potentiate tumor cell cytotoxicity.
摘要翻译：本发明涉及用于激活LT-β受体信号传导的组合物和方法，其又引起对肿瘤细胞的有效的抗增殖作用。更具体地，本发明涉及在淋巴毒素-α与淋巴毒素-β的多个亚基之间形成的淋巴毒素异聚体复合物，其在淋巴毒素-β受体活化剂存在下诱导对肿瘤细胞的细胞毒性作用。在本发明的范围内也是针对淋巴毒素-β受体的抗体，其单独或与其它淋巴毒素-β受体活化剂组合起作用于淋巴毒素-α-β复合物存在或不存在的淋巴毒素-β受体活化剂。提供了选择这种抗体的筛选方法。本发明还涉及使用交联的抗淋巴毒素-β受体抗体单独或在其它淋巴毒素-β受体活化剂存在下增强肿瘤细胞毒性的组合物和方法。

5. 发明申请

WO2008112325A3 TREATMENT OF AUTOIMMUNE DISORDERS 审中-公开
标题翻译：治疗自身免疫性疾病
公开(公告)号：WO2008112325A3
公开(公告)日：2009-12-23
申请号：PCT/US2008003548
申请日：2008-03-17
申请人： BIOGEN IDEC INC , FARRINGTON GRAHAM K , BECKMAN EVAN , BROWNING JEFFREY L , MEIER WERNER
发明人： FARRINGTON GRAHAM K , BECKMAN EVAN , BROWNING JEFFREY L , MEIER WERNER
IPC分类号： C07K14/715
CPC分类号： C07K14/7151 , A61K38/00 , C07K2319/30 , C12N15/62
摘要： Methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. Improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof, are also described.
摘要翻译：用可改善性质的淋巴毒素途径的可溶性抑制剂治疗疾病的方法。还描述了改进的LTBR-Ig融合蛋白及其药物组合物。

6. 发明申请

WO2006017673A2 TAJ IN NEURONAL FUNCTION 审中-公开
标题翻译：神经功能的TAJ
公开(公告)号：WO2006017673A2
公开(公告)日：2006-02-16
申请号：PCT/US2005/027773
申请日：2005-08-03
申请人： BIOGEN IDEC MA INC. , MI, Sha , BROWNING, Jeffrey, L.
发明人： MI, Sha , BROWNING, Jeffrey, L.
IPC分类号： A61K38/17 , A61K48/00 , A61K39/395
CPC分类号： A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A01K2267/0356 , A61K38/191 , A61K48/00 , A61K2039/505 , C07K14/70578 , C07K16/2878 , C07K2319/30 , C12N5/0619 , C12N15/8509 , C12N2501/25 , C12N2517/02 , G01N2333/70575
摘要： The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist.
摘要翻译：本发明提供了通过施用TAJ拮抗剂治疗疾病，病症，损伤或涉及调节神经突生长和/或存活（包括CNS病症，中风或脊髓损伤）的病症的方法。

7. 发明申请

WO2004039329A2 TREATMENT OF IMMUNOLOGICAL RENAL DISORDERS BY LYMPHOTOXIN PATHWAY INHIBITORS 审中-公开
标题翻译： LYMPHOTOXIN路径抑制剂治疗免疫缺陷性疾病
公开(公告)号：WO2004039329A2
公开(公告)日：2004-05-13
申请号：PCT/US2003/034813
申请日：2003-10-31
申请人： BIOGEN, INC. , GOMMERMAN, Jennifer , BROWNING, Jeffrey, L.
发明人： GOMMERMAN, Jennifer , BROWNING, Jeffrey, L.
IPC分类号： A61K
CPC分类号： C07K16/242 , A61K38/1793 , A61K2039/505 , C07K2319/30
摘要： The disclosure relates to treatment of immunological disorders, including but not limited to renal disorders associated with immunoglobulin deposits. The disclosure further relates to the lymphotoxin pathway. Compositions comprising lymphotoxin pathway inhibitors are described.
摘要翻译：本公开涉及免疫学疾病的治疗，包括但不限于与免疫球蛋白沉积相关的肾脏疾病。本公开还涉及淋巴毒素途径。描述了包含淋巴毒素途径抑制剂的组合物。

8. 发明申请

WO2004058191A3 MULTIVALENT LYMPHOTOXIN BETA RECEPTOR AGONISTS AND THERAPEUTIC USES THEREOF 审中-公开
标题翻译：多种LYMPHOTOXINβ受体激动剂及其治疗用途
公开(公告)号：WO2004058191A3
公开(公告)日：2005-12-29
申请号：PCT/US0341393
申请日：2003-12-22
申请人： BIOGEN IDEC INC , GARBER ELLEN , BAILLY VERONIQUE , BROWNING JEFFREY L
发明人： GARBER ELLEN , BAILLY VERONIQUE , BROWNING JEFFREY L
IPC分类号： A61K20060101 , A61K6/00 , A61K39/395 , A61P35/00 , C07K16/28 , C12N15/12 , C12N15/13 , C07K15/06 , A61K37/02
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/622 , C07K2317/64 , C07K2317/73
摘要： Multivalent antibody constructs that are specific for the human lymphotoxin beta receptor, as well as their use in treating cancer and inhibiting tumor volume in a subject are disclosed.
摘要翻译：公开了对人淋巴毒素β受体特异性的多价抗体构建体及其在治疗癌症中的用途以及抑制受试者的肿瘤体积。

9. 发明申请

WO2004039329A3 TREATMENT OF IMMUNOLOGICAL RENAL DISORDERS BY LYMPHOTOXIN PATHWAY INHIBITORS 审中-公开
标题翻译：淋巴毒素途径抑制剂治疗免疫性肾病的研究
公开(公告)号：WO2004039329A3
公开(公告)日：2004-07-15
申请号：PCT/US0334813
申请日：2003-10-31
申请人： BIOGEN INC , GOMMERMAN JENNIFER , BROWNING JEFFREY L
发明人： GOMMERMAN JENNIFER , BROWNING JEFFREY L
IPC分类号： A61K20060101 , A61K38/16 , A61K38/17 , A61K39/395
CPC分类号： C07K16/242 , A61K38/1793 , A61K2039/505 , C07K2319/30
摘要： The disclosure relates to treatment of immunological disorders, including but not limited to renal disorders associated with immunoglobulin deposits. The disclosure further relates to the lymphotoxin pathway. Compositions comprising lymphotoxin pathway inhibitors are described.
摘要翻译：本公开涉及治疗免疫性疾病，包括但不限于与免疫球蛋白沉积相关的肾病。本公开还涉及淋巴毒素途径。描述了包含淋巴毒素途径抑制剂的组合物。

10. 发明申请

WO2012024236A1 LTβR BLOCKADE: METHODS FOR OPTIMIZING THERAPEUTIC RESPONSIVENESS OF PATIENTS 审中-公开
标题翻译： LTßRBLOCKADE：优化患者治疗效果的方法
公开(公告)号：WO2012024236A1
公开(公告)日：2012-02-23
申请号：PCT/US2011/047787
申请日：2011-08-15
申请人： BIOGEN IDEC MA INC. , BIENKOWSKA, Jadwiga , BROWNING, Jeffrey, L.
发明人： BIENKOWSKA, Jadwiga , BROWNING, Jeffrey, L.
IPC分类号： A61K38/21 , C07K14/555 , G01N33/50
CPC分类号： C12Q1/6883 , C12Q2600/166 , G01N33/564 , G01N2800/52
摘要： The invention provides compositions and methods for predicting therapeutic responsiveness of a subject having an autoimmune disorder to an agent that inhibits signaling via LTβR based on the level of expression of IFN or a marker thereof in the subject. The invention also provides methods of treating selected subjects with agents that inhibit or reduce signaling vial LTβR.
摘要翻译：本发明提供了用于根据受试者中IFN或其标志物的表达水平，通过LTβR预测具有自身免疫病症的受试者的治疗反应性的组合物和方法。本发明还提供了用抑制或减少信号小瓶LTβR的试剂治疗所选受试者的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式